
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+7
OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: Tedopi (T-cell specific immunotherapy): Companys most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. OSE-279 (anti-PD1) advanced preclinical stage OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing...
Immuno-oncologie,immunothérapie,maladies autoimmunes,nsclc,checkpoint inhibitor,développement clinique,biotechnologie,néo-épitopes,sirp-alpha,mdsc,rectocolite hémorragique,and polyarthrite rhumatoïde
Ose immunotherapeutics operates in the Biotechnology research industry.
Ose immunotherapeutics's revenue is 1m - 10m
Ose immunotherapeutics has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.